Breaking News Instant updates and real-time market news.

CVS

CVS Health

$65.46

0.42 (0.65%)

, SO

Southern Company

$49.08

0.1 (0.20%)

20:25
08/07/18
08/07
20:25
08/07/18
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include CVS Health (CVS), consensus $1.61... Southern Company (SO), consensus 69c... Thomson Reuters (TRI), consensus 58c... Mylan (MYL), consensus $1.22... Michael Kors (KORS), consensus 95c... Wyndham Destinations (WYND), consensus $1.21... Cinemark (CNK), consensus 76c... Lumentum (LITE), consensus 65c... Sinclair Broadcast (SBGI), consensus 2c... Cars.com (CARS), consensus 26c.

CVS

CVS Health

$65.46

0.42 (0.65%)

SO

Southern Company

$49.08

0.1 (0.20%)

TRI

Thomson Reuters

$40.95

-0.1 (-0.24%)

MYL

Mylan

$38.54

0.81 (2.15%)

KORS

Michael Kors

$65.60

0.98 (1.52%)

WYND

Wyndham Destinations

$45.69

-0.86 (-1.85%)

CNK

Cinemark

$35.97

0.01 (0.03%)

LITE

Lumentum

$57.90

1.8 (3.21%)

SBGI

Sinclair Broadcast

$25.90

(0.00%)

CARS

Cars.com

$28.04

-0.38 (-1.34%)

  • 07

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 09

    Aug

  • 10

    Aug

  • 13

    Aug

  • 25

    Aug

  • 28

    Aug

  • 06

    Sep

  • 12

    Sep

  • 27

    Sep

  • 15

    Oct

  • 13

    Nov

CVS CVS Health
$65.46

0.42 (0.65%)

06/29/18
MZHO
06/29/18
NO CHANGE
MZHO
CVS, Express Scripts should be bought on recent selloff, says Mizuho
Mizuho analyst Ann Hynes recommends buying shares of CVS Health (CVS) and Express Scripts (ESRX) on weakness related to the announcement Amazon (AMZN) is entering the pharmacy space with its acquisition of PillPack. PillPack is a small mail order pharmacy, similar to the mail order pharmacies embedded in CVS Caremark, Express Scripts and OptumRx, Hynes tells investors in a research note.
06/29/18
RBCM
06/29/18
NO CHANGE
Target $84
RBCM
Outperform
CVS Health price target lowered to $84 from $91 at RBC Capital
RBC Capital analyst George Hill lowered his price target on CVS Health Corp (CVS) to $84 after Amazon (AMZN) announced its entry into the pharmacy space with the acquisition of PillPack, even though he believes that the "stickiness of payer/pharmacy relationships, decreasing share of mail order, and PillPack's market share" will not cut margins in near to medium term. Hill keeps his Outperform rating on CVS, noting that it is better positioned to continue to grow its EBIT than Walgreens (WBA). The analyst also sees Amazon's entry into drug distribution raising the possibility of DOJ approval of CVS's Aetna (AET) acquisition.
06/29/18
JEFF
06/29/18
DOWNGRADE
Target $65
JEFF
Hold
Walgreens Boots Alliance downgraded to Hold from Buy at Jefferies
Jefferies analyst Brian Tanquilut downgraded Walgreens Boots Alliance (WBA) to Hold and lowered his price target for the shares to $65 from $85. The stock closed yesterday down 10%, or $6.56, to $59.70. Amazon's (AMZN) acquisition of mail order pharmacy PillPack has "enlarged the overhang" on the retail pharmacy space, Tanquilut tells investors in a research note. The analyst believes the deal could prevent both Walgreens and CVS Health (CVS) from seeing meaningful stock upside near-term. Further, Walgreens' Q3 results, which saw "weak" same-store-sales trends, do not help diffuse the perceived risk that Amazon brings to the company, Tanquilut argues.
07/09/18
SBSH
07/09/18
UPGRADE
Target $81
SBSH
Buy
CVS Health assumed to Buy from Neutral at Citi
Citi analyst Ralph Giacobbe upgraded CVS Health (CVS) to Buy after assuming coverage of the name. The analyst raised his price target for the shares to $81 from $68. While the execution of an integrated healthcare superstore post the pending Aetna (AET) acquisition may be a long way off, the concept will resonate with employers and individuals, Giacobbe tells investors in a research note. He believes deal integration and competitive Amazon (AMZN) risk are "somewhat overstated particularly in the context of heavily discounted valuation."
SO Southern Company
$49.08

0.1 (0.20%)

06/25/18
SBSH
06/25/18
UPGRADE
SBSH
Neutral
Southern Company upgraded to Neutral from Sell at Citi
06/26/18
DBAB
06/26/18
DOWNGRADE
DBAB
Hold
Southern Company downgraded to Hold from Buy at Deutsche Bank
07/10/18
LEHM
07/10/18
INITIATION
Target $51
LEHM
Overweight
Southern Company initiated with an Overweight at Barclays
Barclays analyst Eric Beaumont started Southern Company with an Overweight rating and $51 price target.
07/24/18
HOWW
07/24/18
INITIATION
Target $45
HOWW
Sector Perform
Southern Company initiated with a Sector Perform at Scotia Howard Weil
Scotia Howard Weil analyst Andrew Weisel reinstated Southern Company with a Sector Perform and $45.
TRI Thomson Reuters
$40.95

-0.1 (-0.24%)

05/14/18
ADAM
05/14/18
UPGRADE
ADAM
Buy
Thomson Reuters upgraded to Buy from Hold at Canaccord
05/14/18
RBCM
05/14/18
UPGRADE
RBCM
Outperform
Thomson Reuters upgraded to Outperform from Sector Perform at RBC Capital
05/14/18
RBCM
05/14/18
UPGRADE
Target $44
RBCM
Outperform
Thomson Reuters upgraded to Outperform at RBC Capital on valuation
As reported earlier, RBC Capital analyst Drew McReynolds upgraded Thomson Reuters to Outperform from Sector Perform and kept his $44 price target. The analyst notes that the company's Q1 results were in line with forecasts, while its re-allocation of the previously announced Financial & Risk gross proceeds were also as expected. McReynolds adds that the recent pullback in the stock price offer an attractive entry point, although the stock will have to endure a "digestion period" following the transaction.
06/14/18
PIPR
06/14/18
NO CHANGE
Target $45
PIPR
Neutral
Thomson Reuters price target raised to $45 from $40 at Piper Jaffray
Piper Jaffray analyst Peter Appert raised his price target for Thomson Reuters to $45 citing a more positive view of the company's "long-term value opportunity" and appreciation in the peer group. There is a "potentially interesting multi-year value case" to be made for Thomson, made more compelling by the stock's weakness over the past six months, Appert tells investors in a research note. The analyst, however, keeps a Neutral rating on the shares citing "an evolving financial model and soft near-term earnings expectations."
MYL Mylan
$38.54

0.81 (2.15%)

07/25/18
WELS
07/25/18
NO CHANGE
WELS
Market Perform
Even minor delays can hurt Mylan's generic Advair opportunity, says Wells Fargo
After GlaxoSmithKline (GSK) reported U.S. Advair sales declined 43% at constant currency in Q2, Wells Fargo analyst David Maris commented on the read-through to the generic Advair opportunity being pursued by Mylan (MYL). Given the substantial declines branded Advair faces, he said that "even minor delays" can continue to hurt the potential generic opportunity, adding that he has not seen or been notified of any updates from Mylan on Advair since the company was notified in early June that the FDA planned to issue an official Complete Response Letter related to its application. Maris keeps a Market Perform rating on Mylan shares.
07/12/18
JEFF
07/12/18
NO CHANGE
Target $200
JEFF
Buy
Mlyan priced Amgen biosimilar at 33% discount, says Jefferies
Jefferies analyst Michael Yee says Mylan (MYL) priced its biosimilar to Amgen's Neulasta at a 33% discount to the gross price of branded Neulasta. While the discount is slightly more than initial expectations of 10%-20%, the key is knowing what level of rebating Mylan will be offering to hospitals, Yee tells investors in a research note. The analyst admits, however, that Mylan's Fulphila price "indeed undercuts" Amgen. He keeps a Buy rating on Amgen shares with a $200 price target.
07/18/18
WELS
07/18/18
NO CHANGE
WELS
Novartis report has negative read through for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis (NVS) lowered its 2018 guidance for Sandoz along with its Q2 report and reportedly told Bloomberg that it would consider selling the generic drug unit. He sees a negative read through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL), from Novartis' report, Maris tells investors. He also noted that Novartis said it will not increase prices on its drugs in the U.S. for the rest of 2018, as Pfizer (PFE) recently has also said, calling this "a wise approach and correct read of the increasing intensity of the scrutiny around rising healthcare costs." Maris continues to expect the " chilling effect" on price increases to spread through the industry. Lastly, the analyst pointed out that the Amgen-partnered (AMGN) launch of Aimovig is off to a strong start, which he believes bodes well for Teva's fremanezumab and Eli Lilly's (LLY) galcanezumab.
08/02/18
WELS
08/02/18
NO CHANGE
WELS
Market Perform
Mylan may have negative read-through from Teva report, says Wells Fargo
Wells Fargo analyst David Maris highlighted some items in Teva's (TEVA) Q2 earnings report and conference call that he believes may have a negative read-through for Mylan (MYL). For one, Teva management said they expect the North American generics environment to remain challenging. Additionally, Copaxone sales were relatively flat sequentially, which would be a negative for Mylan if expectations are for increased contribution from Mylan's Copaxone generic in Q2. Mylan has a large pipeline of biosimilars and Teva mentioned it is building a facility for biosimilars in Germany, which indicates more competition, added Maris, who keeps a Market Perform rating on Mylan shares.
KORS Michael Kors
$65.60

0.98 (1.52%)

05/31/18
NEED
05/31/18
NO CHANGE
Target $75
NEED
Buy
Michael Kors pullback a buying opportunity, says Needham
Needham analyst Rick Patel views yesterday's pullback on Michael Kors shares as a buying opportunity, calling Kors a "turnaround story with traction." In a research note to investors, Patel, who maintained a Buy rating and $75 price target, noted that Kors has a history of beating EPS targets and took a "conservative" approach to fiscal 2019 plans. He also contended that guidance for lower wholesale revenues does not reflect weak underlying demand, and sees accessories at Jimmy Choo improving as new products launch this fall.
06/21/18
UBSW
06/21/18
INITIATION
Target $70
UBSW
Neutral
Michael Kors initiated with a Neutral at UBS
UBS analyst Jay Sole started Michael Kors with a Neutral rating and $70 price target.
07/09/18
HSBC
07/09/18
INITIATION
Target $88
HSBC
Buy
Michael Kors initiated with a Buy at HSBC
HSBC initiated Michael Kors with a Buy and $88 price target.
07/09/18
07/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. GameStop (GME) initiated with a Buy at Jefferies. 2. Michael Kors (KORS) initiated with a Buy at HSBC. 3. Weight Watchers (WTW) initiated with a Neutral at UBS. 4. U.S. Xpress Enterprises (USX) initiated with an Overweight at Morgan Stanley and JPMorgan, an Outperform at Wells Fargo, as well as a Buy at Stifel and BofA/Merrill. 5. Charah Solutions (CHRA) initiated with an Overweight at Morgan Stanley and First Analysis, a Buy at Stifel, and a Neutral at BofA/Merrill.This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
WYND Wyndham Destinations
$45.69

-0.86 (-1.85%)

07/16/18
JEFF
07/16/18
INITIATION
Target $65
JEFF
Buy
Wyndham Destinations initiated with a Buy at Jefferies
Jefferies analyst David Katz started Wyndham Destinations with a Buy rating and $65 price target. The recently split company should benefit from more focused strategies and capital allocation, Katz tells investors in a research note. He sees incremental revenue opportunities from its new Blue Thread initiative.
06/14/18
06/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Spotify (SPOT) initiated with a Hold at Deutsche Bank. 2. Hannon Armstrong (HASI) initiated with an Overweight at JPMorgan. 3. Wyndham Hotels & Resorts (WH) and Wyndham Destinations (WYND) were initiated with a Buy at SunTrust. 4. RigNet (RNET) initiated with a Buy at Maxim. 5. Roku (ROKU) initiated with an Outperform at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, Reference Link
06/14/18
RHCO
06/14/18
INITIATION
Target $71
RHCO
Buy
Wyndham Hotels & Resorts initiated with a Buy at SunTrust
SunTrust analyst C. Patrick Scholes initiated Wyndham Hotels & Resorts (WH) with a Buy rating and a price target of $71 and also assumed Wyndham Destinations (WYND) with a Buy rating and a price target of $69 following their spinoff from Wyndham Worldwide that was finalized on June 1st. The analyst contends that the former offers a "straightforward" business model, with a growing pipeline and revenues derived primarily from its franchise fees, benefiting from a strong position in Economy and Midscale travel segments. Scholes also expects Wyndham Hotels to post a stronger RevPAR following its acquisition of LaQuinta (LQ). For the latter, the analyst cites favorable leisure travel tailwinds, a 10% free cash flow yield, and an attractive valuation, along with few signs of investor apprehension within the timeshare securitization market.
06/14/18
RHCO
06/14/18
INITIATION
Target $69
RHCO
Buy
Wyndham Destinations initiated with a Buy at SunTrust
SunTrust initiated Wyndham Destinations with a Buy and $69 price target.
CNK Cinemark
$35.97

0.01 (0.03%)

04/05/18
MOFT
04/05/18
UPGRADE
MOFT
Neutral
Cinemark upgraded to Neutral from Sell at MoffettNathanson
07/11/18
07/11/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alphabet (GOOGL, GOOG), Facebook (FB), and Spotify (SPOT) were initiated with a Buy at Nomura Instinet while Twitter (TWTR) was initiated with a Reduce. 2. AMC Entertainment (AMC) and Cinemark (CNK) were initiated with an Outperform at Imperial Capital. 3. Keurig Dr Pepper (KDP) initiated with a Hold at Stifel. 4. Myers Industries (MYE) initiated with a Neutral at Baird and JPMorgan. 5. TPG Pace Energy (TPGE) initiated with an Outperform at Northland. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/18
IMPC
07/11/18
INITIATION
Target $46
IMPC
Outperform
Cinemark initiated with an Outperform at Imperial Capital
Imperial Capital analyst David Miller started Cinemark Holdings with an Outperform rating and $46 price target. Cinemark is the "highest quality name in the exhibition sub-space," Miller tells investors in a research note. He believes the company offers "impressive" unit growth, "enviable" cost management, a "strong" balance sheet, industry-leading margins and a "robust" dividend, all at a value multiple.
04/05/18
04/05/18
UPGRADE

Neutral
Cinemark upgraded to Neutral at MoffettNathanson
As previously reported, MoffettNathanson upgraded Cinemark to Neutral from Sell with a $35 price target. Analyst Robert Fishman said risk/reward is balanced following strong Q1 results.
LITE Lumentum
$57.90

1.8 (3.21%)

07/23/18
DADA
07/23/18
NO CHANGE
Target $92
DADA
Buy
Lumentum price target lowered to $92 from $104 at DA Davidson
DA Davidson analyst Mark Kelleher lowered his price target on Lumentum to $92 following revenue guidance of a 10% sequential decline from Win Semi on Friday. The analyst notes that Win Semi is predictive for Lumentum as its "contract manufacturer of 3D sensing components", suggesting that "certain 3D laser smartphone customers are experiencing an inventory correction". Kelleher further notes that the inventory overhang is likely due to "Apple (AAPL) building up inventory ahead of the next iPhone cycle", though he does not expect the development to be "indicative of a change in the competitive landscape, or a change in Apple's plans to incorporate 3D sensing into its products". The analyst also keeps his Buy rating on Lumentum.
07/20/18
NEED
07/20/18
NO CHANGE
NEED
Lumentum should be bought on today's weakness, says Needham
Needham analyst Alex Henderson attributes the selloff today in shares of Lumentum to comments from Win Semiconductors, the supplier of VCSEL wafers to Lumentum. It has been reported that Win expects VCSEL sales in the second half of 2018 to be less than previously expected and up less than 100% year-over-year, which is being seen as a negative for Lumentum, Henderson tells investors in a research note. The analyst disagrees. He says shipments in Q2 were well above industry demand as the iPhone X demand fell off and Win couldn't slow production to match the market swing. Henderson believes Win's comments reflect its long lead times. He recommends using the selloff today in shares of Lumentum as a buying opportunity. The analyst keeps a Strong Buy rating on the name with an $80 price target.
07/20/18
NEED
07/20/18
NO CHANGE
NEED
Lumentum selloff today a buying opportunity, says Needham
08/07/18
LOOP
08/07/18
NO CHANGE
Target $73
LOOP
Buy
Lumentum price target lowered to $73 from $78 at Loop Capital
Loop Capital analyst James Kisner lowered his price target on Lumentum to $73 ahead of its Q3 results on August 8th, citing "minor adjustments" to forward expectations around optical component revenue contribution. The analyst keeps his Buy rating, adding that 3D sensing revenue expectations are "achievable", with the company likely to post an in-line Q3 result along with "slightly-better-than-consensus guidance", leading to upside in the stock price. Kisner further notes that he expects "an increasing number of smartphones to utilize the 3D sensing technology" and remains "very bullish" on that segment.
SBGI Sinclair Broadcast
$25.90

(0.00%)

07/27/18
SPHN
07/27/18
NO CHANGE
SPHN
Reported DOJ investigation likely to pressure broadcaster stocks, says Stephens
After The Wall Street Journal reported yesterday that the Department of Justice is investigating whether TV station owners violated antitrust law in ways that inflated local ad prices, Stephens analyst Kyle Evans said that the negative news is likely to further pressure a group that he sees being "hard to own in any quarter." Evans added that, in his view, any miss within the group seems to drag them all down. Publicly traded broadcasters include Sinclair (SBGI), Tribune Media (TRCO), Gray Television (GTN), Nexstar (NXST) and Tegna (TGNA).
07/27/18
WELS
07/27/18
NO CHANGE
WELS
DOJ broadcast investigation unlikely to be material, says Wells Fargo
Wells Fargo analyst Marci Ryvicker says her conversions with industry contacts indicate the Department of Justice investigation into various television groups for alleged ad-rate collusion is unlikely to be material. The investigation likely stemmed from the DOJ's review of the Sinclair Broadcast (SBGI), Tribune Media merger, Ryvicker tells investors in a research note. She believes high levels of conversations about business likely drove the investigation and that it will be tough to prove that this lead to price fixing.
07/19/18
SPHN
07/19/18
DOWNGRADE
Target $37
SPHN
Equal Weight
Tribune Media downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Kyle Evans downgraded Tribune Media (TRCO) to Equal Weight from Overweight after the FCC announced last night that it has adopt a Hearing Designation Order for the Sinclair Broadcast (SBGI) deal. He had hoped the revised divestiture plan would eliminate the need for an HDO, but now that it has been adopted he is more worried that there could be character issues standing in the way of the deal being closed. Evans lowered his price target on Tribune shares to $37 from $41.
07/31/18
EVER
07/31/18
INITIATION
Target $34
EVER
In Line
Sinclair Broadcast initiated with an In Line at Evercore ISI
Evercore ISI analyst David Joyce initiated Sinclair Broadcast with an In Line and $34 price target.
CARS Cars.com
$28.04

-0.38 (-1.34%)

05/30/18
DADA
05/30/18
NO CHANGE
Target $34
DADA
Buy
Cars.com progressing with execution and growth, says DA Davidson
DA Davidson analyst Tom White kept his Buy rating and $34 price target on Cars.com (CARS), saying it "continues to make progress improving its execution, competitive resilience, and growth trajectory since its spin-off." The analyst adds that his takeaways from the latest investor call has made him incrementally more confident in the company's positioning and growth potential. White further states that the third-party shutdowns and product developments at Facebook (FB) are "underappreciated" by investors as they have positioned Cars.com as a "value-added intermediary for car dealers interested in deploying ad dollars on its platform".
05/10/18
RILY
05/10/18
NO CHANGE
Target $37
RILY
Buy
Cars.com earnings selloff a buying opportunity, says B. Riley FBR
B. Riley FBR analyst Sameet Sinha views yesterday's post-earnings selloff in shares of Cars.com as a buying opportunity. The analyst keeps a Buy rating on the shares with a $37 price target.
04/17/18
DADA
04/17/18
NO CHANGE
Target $34
DADA
Buy
Marketing program expansion by automakers to boost Cars.com, says DA Davidson
DA Davidson analyst Tom White writes that expansion of co-op marketing initiatives by automakers, such as the one announced by Ford (F) last month, should create a "material tailwind" for online auto marketplaces like Cars.com (CARS). White notes that automakers' participation in these programs gives the dealers more flexibility on where the marketing funds can be allocated, allowing for promotion of any areas of their business. The analyst expects this trend to continue for a couple of years, keeping his Buy rating and $34 price target on Cars.com.
04/04/18
DADA
04/04/18
INITIATION
Target $41
DADA
Neutral
CarGurus initiated with a Neutral at DA Davidson
DA Davidson analyst Tom White initiated CarGurus (CARG) with a Neutral rating and a price target of $41. White says the company has "deftly" achieved scale on both supply and demand side of its platform within a "complex" online automotive market. The analyst adds that the momentum of user engagement from 2017 looks set to continue this year, but also cites potential risks to CarGurus, including intensifying competition from Cars.com (CARS), execution risk from international expansion, and the expiry of IPO lock-up on April 10th.

TODAY'S FREE FLY STORIES

01:45
08/16/18
08/16
01:45
08/16/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

AVLR

Avalara

$34.68

-1.375 (-3.81%)

23:51
08/15/18
08/15
23:51
08/15/18
23:51
Upgrade
Avalara rating change at Goldman Sachs »

Avalara upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$70.61

-0.56 (-0.79%)

23:22
08/15/18
08/15
23:22
08/15/18
23:22
Hot Stocks
SK Telecom deploys Xilinx FPGAs for AI acceleration »

Xilinx jointly announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVC

Invacare

$16.50

0.15 (0.92%)

21:30
08/15/18
08/15
21:30
08/15/18
21:30
Downgrade
Invacare rating change at KeyBanc »

Invacare downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

PRO

Pros Holdings

$35.39

-1.91 (-5.12%)

20:39
08/15/18
08/15
20:39
08/15/18
20:39
Syndicate
Pros Holdings 3.8M share Secondary priced at $34.00 »

It appears selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 06

    Sep

  • 07

    Sep

  • 16

    Aug

IIN

IntriCon

$63.85

-4.9 (-7.13%)

20:34
08/15/18
08/15
20:34
08/15/18
20:34
Syndicate
IntriCon 1.5M share Secondary priced at $55.00 »

Stifel acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 16

    Aug

ADUS

Addus HomeCare

$59.35

-3.1 (-4.96%)

20:33
08/15/18
08/15
20:33
08/15/18
20:33
Syndicate
Addus HomeCare 2.1M share Secondary priced at $59.00 »

Jefferies, RBC Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

LABL

Multi-Color

$63.90

-1 (-1.54%)

20:32
08/15/18
08/15
20:32
08/15/18
20:32
Downgrade
Multi-Color rating change at KeyBanc »

Multi-Color downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$90.24

-0.565 (-0.62%)

, JCP

J.C. Penney

$2.40

-0.24 (-9.09%)

20:25
08/15/18
08/15
20:25
08/15/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

WMT

Walmart

$90.24

-0.565 (-0.62%)

JCP

J.C. Penney

$2.40

-0.24 (-9.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

WUBA

58.com

$58.59

-3.27 (-5.29%)

19:09
08/15/18
08/15
19:09
08/15/18
19:09
Hot Stocks
Breaking Hot Stocks news story on 58.com »

58.com sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

WUBA

58.com

$58.59

-3.27 (-5.29%)

19:08
08/15/18
08/15
19:08
08/15/18
19:08
Earnings
58.com reports Q2 adjusted earnings per ADS 82c, consensus 68c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

WAIR

Wesco Aircraft

$13.65

-0.3 (-2.15%)

19:07
08/15/18
08/15
19:07
08/15/18
19:07
Initiation
Wesco Aircraft initiated at UBS »

Wesco Aircraft initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGI

Triumph Group

$21.10

-0.9 (-4.09%)

19:07
08/15/18
08/15
19:07
08/15/18
19:07
Initiation
Triumph Group initiated at UBS »

Triumph Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXL

Hexcel

$68.40

-1.13 (-1.63%)

19:06
08/15/18
08/15
19:06
08/15/18
19:06
Initiation
Hexcel initiated at UBS »

Hexcel initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ERJ

Embraer

$18.64

-0.495 (-2.59%)

19:05
08/15/18
08/15
19:05
08/15/18
19:05
Initiation
Embraer initiated at UBS »

Embraer initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CW

Curtiss-Wright

$130.92

-2.42 (-1.81%)

19:04
08/15/18
08/15
19:04
08/15/18
19:04
Initiation
Curtiss-Wright initiated at UBS »

Curtiss-Wright initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$208.08

-1.73 (-0.82%)

19:03
08/15/18
08/15
19:03
08/15/18
19:03
Initiation
L3 Technologies initiated at UBS »

L3 Technologies initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$192.29

-1.33 (-0.69%)

19:03
08/15/18
08/15
19:03
08/15/18
19:03
Initiation
General Dynamics initiated at UBS »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

$0.00

(0.00%)

19:02
08/15/18
08/15
19:02
08/15/18
19:02
Initiation
Bombardier initiated at UBS »

Bombardier initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEI

Heico

$76.50

-1.81 (-2.31%)

19:00
08/15/18
08/15
19:00
08/15/18
19:00
Initiation
Heico initiated at UBS »

Heico initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 13

    Sep

  • 06

    Nov

HRS

Harris

$162.73

-2.15 (-1.30%)

18:59
08/15/18
08/15
18:59
08/15/18
18:59
Initiation
Harris initiated at UBS »

Harris initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$291.52

-2.35 (-0.80%)

18:59
08/15/18
08/15
18:59
08/15/18
18:59
Initiation
Northrop Grumman initiated at UBS »

Northrop Grumman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNC

PNC Financial

$142.03

-0.7 (-0.49%)

, WFC

Wells Fargo

$57.99

-0.08 (-0.14%)

18:57
08/15/18
08/15
18:57
08/15/18
18:57
Periodicals
PNC faces subpoenas over low-income housing tax credits, Bloomberg says »

PNC Financial (PNC) has…

PNC

PNC Financial

$142.03

-0.7 (-0.49%)

WFC

Wells Fargo

$57.99

-0.08 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

UTX

United Technologies

$131.75

-0.65 (-0.49%)

18:57
08/15/18
08/15
18:57
08/15/18
18:57
Initiation
United Technologies initiated at UBS »

United Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

B

Barnes Group

$65.59

-0.26 (-0.39%)

18:56
08/15/18
08/15
18:56
08/15/18
18:56
Initiation
Barnes Group initiated at UBS »

Barnes Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.